Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials

Main Article Content

K Reich
Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation® Center, Hamburg, Germany

A Blauvelt
Oregon Medical Research Center, Portland, Oregon, USA

M Lebwohl
Icahn School of Medicine at Mount Sinai, New York, New York, USA

KA Papp
Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada

P Rich
Oregon Dermatology and Research Center, Portland, Oregon, USA

B Strober
Yale University, New Haven, Connecticut, USA; Central Connecticut Dermatology Research, Cromwell, Connecticut, USA

D De Cuyper
UCB Pharma, Brussels, Belgium

C Madden
UCB Pharma, Raleigh, North Carolina, USA

L Peterson
UCB Pharma, Raleigh, North Carolina, USA

V Vanvoorden
UCB Pharma, Brussels, Belgium

RB Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK

Keywords

Plaque Psoriasis, Biologic, Bimekizumab, Safety

Abstract

Abstract not available.

References

1. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

2. Papp KA. J Am Acad Dermatol 2018;79:277–86 e10.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.21

Article Details

How to Cite
Reich, K., Blauvelt, A., Lebwohl, M., Papp, K., Rich, P., Strober, B., De Cuyper, D., Madden, C., Peterson, L., Vanvoorden, V., & Warren, R. (2021). Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. SKIN The Journal of Cutaneous Medicine, 5(1), s21. https://doi.org/10.25251/skin.5.supp.21
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors transfer copyright to the publisher as part of the journal publishing agreement.

All reprints are subject to the reprint policy.